Adam A. Luczak

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 21, 2026

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: May 21, 2026

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2026

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 19, 2026

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal: Journal of the National Cancer Institute

Published: March 09, 2026

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Journal: International journal of cancer

Published: January 28, 2026

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 23, 2025

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Journal: Journal of the National Cancer Institute

Published: June 24, 2025

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 23, 2025

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

Journal: Gynecologic oncology

Published: September 11, 2024

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.

Journal: Melanoma research

Published: June 09, 2023

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma.

Journal: Cancers

Published: June 02, 2022

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma.

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.